Composite cognitive and functional measures for early stage Alzheimer's disease trials

INTRODUCTION: Composite scales have been advanced as primary outcomes in early stage Alzheimer's disease trials, and endorsed by the U.S. Food and Drug Administration (FDA) for pivotal trials. They are generally composed of several neurocognitive subscales and may include clinical and functiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Lon S., Goldberg, Terry E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233425/
https://www.ncbi.nlm.nih.gov/pubmed/32432155
http://dx.doi.org/10.1002/dad2.12017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233425/
https://www.ncbi.nlm.nih.gov/pubmed/32432155
http://dx.doi.org/10.1002/dad2.12017

Ejemplares similares